AM Investment Strategies LLC Has $1.02 Million Position in Eli Lilly and Company (NYSE:LLY)

AM Investment Strategies LLC lifted its position in shares of Eli Lilly and Company (NYSE:LLY) by 256.1% during the 4th quarter, Holdings Channel reports. The firm owned 1,321 shares of the company’s stock after purchasing an additional 950 shares during the quarter. AM Investment Strategies LLC’s holdings in Eli Lilly and Company were worth $1,020,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently modified their holdings of the company. Exchange Traded Concepts LLC grew its holdings in Eli Lilly and Company by 13.9% during the fourth quarter. Exchange Traded Concepts LLC now owns 38,810 shares of the company’s stock worth $29,961,000 after purchasing an additional 4,733 shares during the period. CX Institutional boosted its stake in shares of Eli Lilly and Company by 23.2% during the 4th quarter. CX Institutional now owns 23,623 shares of the company’s stock worth $18,237,000 after acquiring an additional 4,452 shares during the period. Berbice Capital Management LLC bought a new position in shares of Eli Lilly and Company during the 4th quarter worth approximately $673,000. Impact Partnership Wealth LLC increased its holdings in shares of Eli Lilly and Company by 42.5% during the 4th quarter. Impact Partnership Wealth LLC now owns 1,022 shares of the company’s stock worth $789,000 after acquiring an additional 305 shares during the last quarter. Finally, Sound Income Strategies LLC raised its stake in Eli Lilly and Company by 0.8% in the 4th quarter. Sound Income Strategies LLC now owns 4,814 shares of the company’s stock valued at $3,716,000 after acquiring an additional 38 shares during the period. 82.53% of the stock is owned by institutional investors.

Insider Activity at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 900 shares of the stock in a transaction on Friday, November 8th. The stock was sold at an average price of $803.38, for a total value of $723,042.00. Following the completion of the transaction, the chief accounting officer now directly owns 5,480 shares in the company, valued at approximately $4,402,522.40. This represents a 14.11 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.13% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

LLY has been the subject of a number of research analyst reports. Citigroup lifted their price objective on shares of Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the stock a “buy” rating in a research report on Friday, October 25th. Truist Financial upped their price target on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a research note on Thursday, October 10th. Barclays cut their price objective on shares of Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating for the company in a research report on Thursday, October 31st. Wolfe Research initiated coverage on Eli Lilly and Company in a research report on Friday, November 15th. They issued an “outperform” rating and a $1,000.00 target price on the stock. Finally, Bank of America reissued a “buy” rating and set a $997.00 price target on shares of Eli Lilly and Company in a report on Tuesday, December 10th. Four analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and an average target price of $1,002.22.

Eli Lilly and Company Trading Up 2.4 %

Shares of LLY stock opened at $784.78 on Monday. Eli Lilly and Company has a fifty-two week low of $624.68 and a fifty-two week high of $972.53. The stock’s fifty day moving average price is $776.69 and its two-hundred day moving average price is $848.83. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.97 and a current ratio of 1.27. The company has a market cap of $745.01 billion, a PE ratio of 84.84, a P/E/G ratio of 1.59 and a beta of 0.41.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing the consensus estimate of $1.52 by ($0.34). The business had revenue of $11.44 billion during the quarter, compared to analyst estimates of $12.09 billion. Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The business’s quarterly revenue was up 20.4% compared to the same quarter last year. During the same period last year, the business earned $0.10 earnings per share. Equities analysts predict that Eli Lilly and Company will post 12.98 EPS for the current fiscal year.

Eli Lilly and Company declared that its board has approved a stock repurchase plan on Monday, December 9th that permits the company to repurchase $15.00 billion in shares. This repurchase authorization permits the company to repurchase up to 2% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s management believes its shares are undervalued.

Eli Lilly and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Investors of record on Friday, February 14th will be given a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a yield of 0.76%. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.30. The ex-dividend date of this dividend is Friday, February 14th. Eli Lilly and Company’s dividend payout ratio is currently 56.22%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.